2. Search Result
Search Result
Results for "

T2DM

" in MedChemExpress (MCE) Product Catalog:

68

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

1

Inhibitory Antibodies

7

Natural
Products

2

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3366
    Ecnoglutide

    XW003

    		 GCGR Metabolic Disease
    Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 (GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity [2].
    Ecnoglutide
  • HY-112668
    Retagliptin phosphate
    1 Publications Verification

    SP2086 phosphate

    		 Dipeptidyl Peptidase Metabolic Disease
    Retagliptin phosphate (SP2086 phosphate) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin phosphate can be used for type 2 diabetes mellitus (T2DM) research .
    Retagliptin phosphate
  • HY-112668A
    Retagliptin
    1 Publications Verification

    SP2086

    		 Dipeptidyl Peptidase Metabolic Disease
    Retagliptin (SP2086) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin can be used for type 2 diabetes mellitus (T2DM) research .
    Retagliptin
  • HY-153865
    Lotiglipron

    PF-07081532

    		 GCGR Metabolic Disease
    Lotiglipron (PF-07081532) is an orally active GLP-1R agonist. Lotiglipron reduces glucose and body weight, and can be used for research of Type 2 diabetes mellitus (T2DM) .
    Lotiglipron
  • HY-114191B
    SSTR5 antagonist 2 hydrochloride

    		Somatostatin Receptor Metabolic Disease Endocrinology
    SSTR5 antagonist 2 hydrochloride is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of type 2 diabetes mellitus (T2DM) .
    SSTR5 antagonist 2 hydrochloride
  • HY-12066
    GSK1292263
    3 Publications Verification

    		 GPR119 Metabolic Disease Inflammation/Immunology
    GSK-1292263 is an orally available GPR119 agonist with pEC50s of 6.9 and 6.7 for human and rat GPR119, respectively. GSK-1292263 can be used for the research of type 2 diabetes mellitus (T2DM) .
    GSK1292263
  • HY-163886
    KHK-IN-5

    		Ketohexokinase Metabolic Disease
    KHK-IN-5 (Compound 18) is a KHK inhibitor. KHK-IN-5 can be used for the research of nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and type 2 diabetes (T2DM) .
    KHK-IN-5
  • HY-153113
    Rongliflozin

    DJT1116PG

    		 SGLT Endocrinology
    Rongliflozin (DJT1116PG) is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2). Rongliflozin can be used for the research of type 2 diabetes mellitus (T2DM) .
    Rongliflozin
  • HY-149332
    α-Glucosidase-IN-26

    		Glycosidase Metabolic Disease
    α-Glucosidase-IN-26 (Compound 7i) is an α-glucosidase inhibitor (IC50=4.63 µM). α-Glucosidase-IN-26 can be used in the study of type 2 diabetes mellitus (T2DM) .
    α-Glucosidase-IN-26
  • HY-114191
    SSTR5 antagonist 2

    		Somatostatin Receptor Metabolic Disease Endocrinology
    SSTR5 antagonist 2 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM) .
    SSTR5 antagonist 2
  • HY-114191A
    SSTR5 antagonist 2 TFA

    		Somatostatin Receptor Metabolic Disease Endocrinology
    SSTR5 Antagonist 1 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM) .
    SSTR5 antagonist 2 TFA
  • HY-14928
    Lobeglitazone

    		Others Metabolic Disease
    Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone can be used to prevent type 2 diabetes mellitus (T2DM) .
    Lobeglitazone
  • HY-14928A
    Lobeglitazone sulfate

    		Others Metabolic Disease
    Lobeglitazone sulfate is a new type of thiazolidinedione. Lobeglitazone sulfate can be used to prevent type 2 diabetes mellitus (T2DM) .
    Lobeglitazone sulfate
  • HY-152158
    α-Glucosidase-IN-22

    		Glycosidase Metabolic Disease
    α-Glucosidase-IN-22 (compound 7i), a benzimidazole, is a potent α-glucosidase inhibitor with an IC50 of 0.64 μM. α-Glucosidase-IN-22 is a potent anti-diabetic agent and has the potential for type 2 diabetes mellitus (T2DM) research .
    α-Glucosidase-IN-22
  • HY-P0119A
    Lixisenatide acetate
    2 Publications Verification

    		 GCGR Metabolic Disease
    Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).
    Lixisenatide acetate
  • HY-P99614
    Fazpilodemab

    BFKB8488A

    		 FGFR Metabolic Disease
    Fazpilodemab (BFKB8488A) is a humanized, agonistic, bispecific antibody targeting fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD) .
    Fazpilodemab
  • HY-158037
    α-Glucosidase-IN-55

    		Glycosidase Metabolic Disease
    α-Glucosidase-IN-55 (Compound 8g) is an orally active and competitive alpha-glucosidase inhibitor, with IC50 and Ki values of 12.1 and 9.66 µM, respectively. α-Glucosidase-IN-55 can be used for the research into type 2 diabetes mellitus (T2DM) to improve blood sugar control and metabolic health .
    α-Glucosidase-IN-55
  • HY-W587977
    3-Hydroxypalmitoylcarnitine

    3-Hydroxyhexadecanoylcarnitine

    		 Biochemical Assay Reagents Cardiovascular Disease Metabolic Disease
    3-Hydroxypalmitoylcarnitine (3-Hydroxyhexadecanoylcarnitine) is an acylcarnitine. Elevated levels of 3-Hydroxypalmitoylcarnitine are associated with cardiovascular disease (CVD) in type 2 diabetes mellitus (T2DM) .
    3-Hydroxypalmitoylcarnitine
  • HY-14928S1
    Lobeglitazone-d4

    		Isotope-Labeled Compounds Others Metabolic Disease
    Lobeglitazone-d4 is deuterium labeled Lobeglitazone. Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone can be used to prevent type 2 diabetes mellitus (T2DM) [2].
    Lobeglitazone-d4
  • HY-19947
    PF-06291874
    1 Publications Verification

    Glucagon receptor antagonists-4

    		 GCGR Metabolic Disease
    PF-06291874 is a highly potent, non-peptide and orally active glucagon receptor antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM) [2].
    PF-06291874
  • HY-132205
    DS45500853

    		Estrogen Receptor/ERR Metabolic Disease
    DS45500853 is an estrogen-related receptor α (ERRα) agonist. DS45500853 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC50 value of 0.80 μM. DS45500853 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM) .
    DS45500853
  • HY-15408
    Trelagliptin

    SYR-472

    		 Dipeptidyl Peptidase Metabolic Disease
    Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .
    Trelagliptin
  • HY-149579
    α-Glucosidase-IN-36

    		Glycosidase Metabolic Disease
    α-Glucosidase-IN-36 (compound 5g) is a potent α-glucosidase inhibitor, with an IC50 of 6.69 ± 0.18 μM, Ki and Kis of 1.65 μM and 4.54 μM, respectively. α-Glucosidase-IN-36 may inhibit α-glucosidase activity by binding with its active site as well as changing the secondary structure of α-glucosidase. α-Glucosidase-IN-36 can be used for type 2 diabetes mellitus (T2DM) research .
    α-Glucosidase-IN-36
  • HY-15408A
    Trelagliptin succinate

    SYR-472 succinate

    		 Dipeptidyl Peptidase Metabolic Disease
    Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .
    Trelagliptin succinate
  • HY-10449A
    Luseogliflozin hydrate

    TS 071 hydrate

    		 SGLT Metabolic Disease
    Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM) [2].
    Luseogliflozin hydrate
  • HY-147257
    Cofrogliptin

    HSK7653

    		 Dipeptidyl Peptidase Metabolic Disease
    Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) .
    Cofrogliptin
  • HY-128781
    Glucagon receptor antagonists-5

    		GCGR Metabolic Disease
    Glucagon receptor antagonists-5 (compound 13K) is a potent and orally bioavailable indazole-based glucagon receptor antagonist (Ki=32 nM). Glucagon receptor antagonists-5 has potential for the treatment of type 2 diabetes mellitus (T2DM) .
    Glucagon receptor antagonists-5
  • HY-159696A
    ISIS 449884 sodium

    		GCGR Metabolic Disease
    ISIS 449884 sodium is a 2'-O-methoxyethyl antisense oligonucleotide that targets GCGR. ISIS 449884 sodium has an ability to reduce hepatic glucose output and lower the blood glucose level. ISIS 449884 sodium can be used for the study of type 2 diabetes mellitus (T2DM) .
    ISIS 449884 sodium
  • HY-159696
    ISIS 449884

    		GCGR Metabolic Disease
    ISIS 449884 is a 2'-O-methoxyethyl antisense oligonucleotide that targets GCGR. ISIS 449884 has an ability to reduce hepatic glucose output and lower the blood glucose level. ISIS 449884 can be used for the study of type 2 diabetes mellitus (T2DM) .
    ISIS 449884
  • HY-119222
    GSK256073
    2 Publications Verification

    		 GPR109A Metabolic Disease
    GSK256073 is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia [2]. GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2
    GSK256073
  • HY-119222A
    GSK256073 tris

    		GPR109A Metabolic Disease
    GSK256073 tris is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 tris acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia [2]. GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2
    GSK256073 tris
  • HY-B1021
    Vincamine
    1 Publications Verification

    		 Free Fatty Acid Receptor Cardiovascular Disease Metabolic Disease
    Vincamine?is a monoterpenoid indole alkaloid extracted from the?Madagascar periwinkle. Vincamine?is a peripheral?vasodilator?and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine?is a?GPR40?agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS).?Vincamine?improves glucose homeostasis?in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research [2].
    Vincamine
  • HY-153798
    GLP-1 receptor agonist 10

    		GLP Receptor Metabolic Disease
    GLP-1 receptor agonist 10 (compound 42) is an agonist of GLP Receptor. GLP-1 receptor agonist 10 inhibits food intake and reduces glucose excursion in mice. GLP-1 receptor agonist 10 can be used in the study of type 2 diabetes (T2DM) and obesity .
    GLP-1 receptor agonist 10
  • HY-163996
    DD202-114

    		GLP Receptor Metabolic Disease
    DD202-114 is a potent and selective GLP1R agonist. DD202-114 promots cAMP accumulation. DD202-114 reduces blood glucose levels and food intake. DD202-114 has the potential for the research of type 2 diabetes (T2DM) and obesity .
    DD202-114
  • HY-15408AR
    Trelagliptin (succinate) (Standard)

    		Dipeptidyl Peptidase Metabolic Disease
    Trelagliptin (succinate) (Standard) is the analytical standard of Trelagliptin (succinate). This product is intended for research and analytical applications. Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .
    Trelagliptin (succinate) (Standard)
  • HY-15408S
    Trelagliptin-13C,d3

    SYR-472-13C,d3

    		 Isotope-Labeled Compounds Dipeptidyl Peptidase Metabolic Disease
    Trelagliptin-13C,d3 is a deuterated labeled Trelagliptin . Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) [2].
    Trelagliptin-13C,d3
  • HY-B1021R
    Vincamine (Standard)

    		Free Fatty Acid Receptor Cardiovascular Disease Metabolic Disease
    Vincamine (Standard) is the analytical standard of Vincamine. This product is intended for research and analytical applications. Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research [2].
    Vincamine (Standard)
  • HY-19835
    LY2922470

    		Free Fatty Acid Receptor Metabolic Disease
    LY2922470 is a potent, selective and orally available agonist of the G protein-coupled receptor 40 (GPR40), with EC50s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. LY2922470 reduces glucose levels along with significant increases in insulin and GLP-1, is potential for the treatment of type 2 diabetes mellitus (T2DM) .
    LY2922470
  • HY-143201
    DS20362725

    		Estrogen Receptor/ERR Metabolic Disease
    DS20362725 is an estrogen-related receptor α (ERRα) agonist. DS20362725 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC50 value of 0.6 μM. DS20362725 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM) .
    DS20362725
  • HY-150701
    INCB13739

    		Glucocorticoid Receptor Mineralocorticoid Receptor 11β-HSD Metabolic Disease
    INCB13739 is an orally active, potent, selective and tissue-specific11β-HSD1 (11β-hydroxysteroid dehydrogenase 1) inhibitor, with IC50 values of 3.2 nM (11β-HSD1 enzymatic) and 1.1 nM (11β-HSD1 PBMC), respectively. INCB13739 can be used for type 2 diabetes mellitus (T2DM) and obesity research .
    INCB13739
  • HY-149255
    PTP1B/AKR1B1-IN-2

    		Phosphatase Aldose Reductase Metabolic Disease
    PTP1B/AKR1B1-IN-2 (Compound 7f) is a dual PTP1B/AKR1B1 inhibitor (IC50s: 3.2 and 2.1 μM, Kis: 4.0 and 0.9μM). PTP1B/AKR1B1-IN-2 is an insulin-mimetic agent. PTP1B/AKR1B1-IN-2 improves glucose uptake in murine C2C12 myoblasts. PTP1B/AKR1B1-IN-2 can be used for research of Type 2 diabetes mellitus (T2DM) .
    PTP1B/AKR1B1-IN-2
  • HY-149254
    PTP1B/AKR1B1-IN-1

    		Phosphatase Aldose Reductase Metabolic Disease
    PTP1B/AKR1B1-IN-1 is a dual inhibitor of protein tyrosine phosphatase 1B (PTP1B) and aldose reductase (AKR1B1), with IC50s of 0.06 μM and 4.3 μM, respectively. PTP1B/AKR1B1-IN-1 also inhibits TC-PTP with an IC50 value of 9 μM. PTP1B/AKR1B1-IN-1 serves as an insulin-mimetic agent in murine myoblasts, and reduces AKR1B1-dependent sorbitol accumulation. PTP1B/AKR1B1-IN-1 inhibits development of type 2 diabetes mellitus (T2DM) to control blood glucose levels .
    PTP1B/AKR1B1-IN-1
  • HY-19842
    GS-9667

    CVT 3619

    		 Adenosine Receptor Cardiovascular Disease Metabolic Disease
    GS-9667 (CVT 3619), a novel N 6-5'-substituted adenosine analog, is a selective, partial agonist of the A1 adenosine receptor (A1AdoR). GS-9667 binds to adipocyte membranes with high (KH=14 nM) and low (KL=5.4 μM) affinities. GS-9667 reduces cyclic AMP content and release of nonesterified fatty acids from epididymal adipocytes with IC50 values of 6 nM and 44 nM, respectively. GS-9667 inhibits lipolysis and has the potential for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA) [2].
    GS-9667
  • HY-155156
    PF-07238025

    		Endogenous Metabolite Cardiovascular Disease
    PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC50=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .
    PF-07238025
  • HY-155157
    PF-07247685

    		Endogenous Metabolite Cardiovascular Disease
    PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC50=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .
    PF-07247685
  • HY-147628
    GLP-1R agonist 15

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 15 (Compound 101) is a GLP-1 receptor agonist .
    GLP-1R agonist 15
  • HY-147623
    GLP-1R agonist 10

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 10 (Compound 109a) is a GLP-1 agonist with an EC50 of 0.051 nM .
    GLP-1R agonist 10
  • HY-147629
    GLP-1R agonist 16

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 16 (Compound 115a) is a GLP-1 receptor agonist with an EC50 of 0.15 nM .
    GLP-1R agonist 16
  • HY-163907
    α-Glucosidase-IN-71

    		Glycosidase Metabolic Disease
    α-Glucosidase-IN-71 (Compound 7h) is a competitive α-glucosidase inhibitor (IC50: 98.0 µM). α-Glucosidase-IN-71 can be used for research of carbohydrate-related diseases, especially type 2 diabetes mellitus .
    α-Glucosidase-IN-71
  • HY-151383
    DPP-4-IN-1

    		Dipeptidyl Peptidase Metabolic Disease
    DPP-4-IN-1 (compound d1) is a potent DPP-4 (dipeptidyl peptidase 4) inhibitor, with an IC50of 49 nM. DPP-4-IN-1 is a structurally analogs of Alogliptin (HY-A0023A). DPP-4-IN-1 can be used for diabetes research .
    DPP-4-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: